English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers at the University of Michigan Health Rogel Cancer Center are exploiting a unique biological feature of glioblastoma to gain a better understanding of how this puzzling brain cancer develops and how to target new treatments against it. The team developed human and mouse models of glioblastoma oncostreams and examined multiple factors in the tumor microenvironment that could impact how oncostreams develop and how to reverse them.
Tag: Gliobastoma
Brain Cancer: Hunting What’s Left
Like a mystery detective, Sara G.M. Piccirillo, PhD, is hunting deadly bad actors by studying the crime scene and questioning bystanders one by one. But these bad actors are cells in the brain. She is using two grants to study tumor cells and cells in the surrounding area, one by one.
Researchers identify potential therapeutic target against malignant brain tumors
Researchers at UAB have identified a potential new pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer. The findings indicate that an adhesive cell surface protein known as N-cad may be key in overcoming glioblastoma’s resistance to radiation therapy.
NIH Funds Research into Differences in Glioblastoma between Males and Females
A team led by researchers from Case Western Reserve University School of Medicine and Cleveland Clinic Lerner Research Institute has secured $10.4 million over five years from the National Institutes of Health/National Cancer Institute to explore at the molecular level the differences in glioblastoma between males and females.
University Hospitals Seidman Cancer Center treats its first glioblastoma patient with genetically modified poliovirus
University Hospitals Seidman Cancer Center treated its first patient in a new clinical trial to validate the groundbreaking effects of the poliovirus on glioblastoma (GBM), a deadly Grade IV cancer of the brain.
UH is the only Midwest site participating in this clinical trial, which was initiated at Duke Cancer Institute in Durham, NC. The original study, which ran from 2012-2017, was published in New England Journal of Medicine in July 2018 as well as highlighted on “60 Minutes” in 2015 and again in 2018. The study found that survival rates were significantly higher in glioblastoma patients who received an intratumoral infusion of a modified viral chimera combining the polio and rhinoviruses (PVSRIPO immunotherapy) compared to patients receiving standard treatment at the same institution.
Exploding shells boost immune response to brain cancer
Researchers at the University of California San Diego figured out a way to combine FDA-approved ultrasound with engineered glass particles to boost the effectiveness of immunotherapy in glioblastomas.